InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.375

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$115 RCE Corporate Presentation 20 Mar 2025 9:44AM $0.390 $0.375 fallen by 3.85%
$115 Key Opinion Leader Presentation 3 Mar 2025 10:08AM $0.425 $0.375 fallen by 11.76%
$115 RCE Clinical Milestones Investor Webinar 28 Feb 2025 12:15PM $0.420 $0.375 fallen by 10.71%
$115 Appendix 4D and Interim Financial Report 28 Feb 2025 8:50AM $0.430 $0.375 fallen by 12.79%
$115 Japan Patent Allowance for RECCE Anti-Infectives 26 Feb 2025 10:12AM $0.445 $0.375 fallen by 15.73%
$115 Positive Phase II Data from Clinical Trial of R327 Gel 17 Feb 2025 9:24AM $0.450 $0.375 fallen by 16.67%
$115 Trading Halt 13 Feb 2025 11:56AM $0.450 $0.375 fallen by 16.67%
$115 Pause in Trading 13 Feb 2025 11:31AM $0.450 $0.375 fallen by 16.67%
$115 Correction to Appendix 4C and Quarterly Activities Report 6 Feb 2025 11:29AM $0.440 $0.375 fallen by 14.77%
$115 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2025 5:26PM $0.460 $0.375 fallen by 18.48%
$115 Patient Dosing Complete in Phase II ABSSSI Trial of R327G 21 Jan 2025 9:57AM $0.470 $0.375 fallen by 20.21%
$115 Regulatory Approval for Registrational Phase 3 R327G Trial 9 Dec 2024 9:05AM $0.470 $0.375 fallen by 20.21%
$115 Trading Halt 5 Dec 2024 9:21AM $0.470 $0.375 fallen by 20.21%
$115 Presentation - Ord Minnett Biotech & MedTech Conference 28 Nov 2024 12:42PM $0.455 $0.375 fallen by 17.58%
$115 Australia Patent Granted for RECCE Anti-Infectives 26 Nov 2024 8:37AM $0.470 $0.375 fallen by 20.21%
$115 Change of Director's Interest Notices 21 Nov 2024 7:31PM $0.470 $0.375 fallen by 20.21%
$115 Notification regarding unquoted securities - RCE 21 Nov 2024 7:21PM $0.470 $0.375 fallen by 20.21%
$115 AUD $6.75m R&D Rebate Approved 14 Nov 2024 10:38AM $0.480 $0.375 fallen by 21.88%
$115 Notification regarding unquoted securities - RCE 13 Nov 2024 5:14PM $0.480 $0.375 fallen by 21.88%
$115 Ethics Approval for Registrational Ph3 R327G Clinical Trial 11 Nov 2024 9:16AM $0.470 $0.375 fallen by 20.21%
$115 Constitution 6 Nov 2024 5:59PM $0.465 $0.375 fallen by 19.35%
$115 Results of Special General Meeting 6 Nov 2024 5:45PM $0.465 $0.375 fallen by 19.35%
$115 Results of Annual General Meeting 6 Nov 2024 5:33PM $0.465 $0.375 fallen by 19.35%
$115 AGM Presentation 6 Nov 2024 9:53AM $0.465 $0.375 fallen by 19.35%
$115 Phase II ABSSSI Clinical Trial Advances to Final Stages 5 Nov 2024 10:12AM $0.445 $0.375 fallen by 15.73%

101 - 125 of 724 results

Page 5 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.